

5 November 2014

ASX & Media Release

New patents allowed for 11 β -HSD1 inhibitor

The Board of Actinogen Limited (ASX: ACW), an Australian biotechnology company, is pleased to announce that European application has been allowed for two new patents in relation to the composition and use of 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) inhibitor currently in clinical development for dementia by Corticrine Ltd.

It was announced on 27 August 2014 that the Company had acquired Corticrine Ltd, subject to shareholder approval.

The two patents under consideration are:

- i. EP Application No: 10755215.0 entitled "*(4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use*"
- ii. EP Application No: 11709770.9 entitled "*3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone and related compounds and their use*"

These patents are in relation to pharmaceutical compositions of 11 β -HSD1 inhibitor and the use of these compounds to inhibit 11 β -HSD1 in order to treat disorders that are ameliorated by the inhibition of this enzyme. The claims in these patents also cover the method to treat various diseases including the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease, CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease, etc.

The Company has been also notified that a similar patent was allowed in Israel (Israel requires application through ILPO – Israel Patent Office).

The patent under consideration is:

- i. IL Application No: 218315 entitled "*(4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use*"

The new patents add to Corticrine's extensive intellectual property portfolio around UE2343 with patents protected until 2028 and beyond. Actinogen is currently preparing for a Phase I Multiple Ascending Dose (MAD) study that should commence early 2015.

-end-

Dr Brendan de Kauwe
Executive Chairman
Actinogen Limited

About Actinogen Limited
Actinogen Limited (ASX: ACW)

Actinogen is a clinical stage Australian biotechnology company focused on the development of novel treatments for Alzheimer's Disease (AD) and other major age-related neurodegenerative disorders. Actinogen's lead candidate UE2343 is a small molecule inhibitor of 11-beta-hydroxysteroid dehydrogenase (11 β -HSD1) an enzyme that reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. There is evidence for a role of glucocorticoids and hypothalamus-pituitary-adrenal axis dysfunction in AD that includes both cortisol-induced neurotoxicity on the hippocampal formation and acute ongoing impairment of cognition. UE2343 was discovered in 2007 at the laboratory of Professor Brian Walker at the University of Edinburgh. Supported by The Wellcome Trust, the University has spent approximately \$25M AUD for the development of UE2343.

In addition, the Company has an early stage drug discovery program focused on developing drugs to treat brain cancer and potentially other oncological diseases by the targeted killing of cancer stem cells (CSCs). The first study was conducted in collaboration with Curtin University and the results demonstrated substantial reduction of proliferation in CSCs populations in glioblastoma cell lines.